Supplementary Figures 1 - 10, Tables 1 - 11 from Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer

Abstract

<p>PDF file - 280KB, Supplementary Table S1. Primers for TP53 genotyping. Supplementary Table S2. Cell lines used as controls for TP53, KRAS, BRAF and PIK3CA genotyping. Supplementary Table S3. Amplification conditions for TP53 genotyping. Supplementary Table S4. Primers for k-RAS, BRAF and PIK3CA genotyping. Supplementary Table S5. Amplification conditions for KRAS, BRAF and PIK3CA genotyping. Supplementary Table S6: Additional clinical and biological characteristics of the patients in the training and validation cohorts, according to EGFR status. Supplementary Table S7: Characteristics of the patients in the training cohort, classified according to EGFR and TP53 status. Supplementary Table S8: List of observed TP53 mutations (training and validation cohorts). Supplementary Table S9: Univariate Cox regression analysis of selected factors for overall survival in the EGFR-wt and EGFR-mut populations of the training cohort. Supplementary Table S10: Results of multivariate analysis of selected factors for overall survival in the EGFR-wt and EGFR-mut groups of the training cohort. Supplementary Table S11: GOF activities in cell line models of some nondisruptive TP53 mutations found in this study. Supplementary Figure S1: Structure of the TP53 protein representing the location of the mutations found in the training cohort. Supplementary Figure S2: Types of TP53 mutations in the training and validation cohorts. Supplementary Figure S3: Distribution of KRAS, BRAF and PIK3CA mutations in the training cohort. Supplementary Figure S4. Kaplan-Meier plots of overall and progression-free survival of the 318 patients in the training cohort, according to EGFR mutational status. Supplementary Figure S5. Kaplan-Meier plots of overall survival of the 125 EGFR-wt patients in the training cohort, according to G12C mutations in K-RAS. Supplementary Figure S6: Kaplan-Meier plots of overall and progression-free survival of the 318 patients in the training cohort, according to TP53 status. Supplementary Figure S7. Kaplan-Meier plots of overall survival of the 110 EGFR-wt patients in the training cohort not carrying G12C mutations in K-RAS. Supplementary Figure S8: Kaplan-Meier plots of progression-free survival of the 318 patients in the training cohort, according to TP53 mutational status. Supplementary Figure S9: Kaplan-Meier plots of progression-free survival in the training cohort, according to EGFR and TP53 mutational status. Supplementary Figure S10: Kaplan-Meier plots of progression-free survival in the training cohort, according to type of treatment.</p>